Tanvex BioPharma USA, Inc., a key subsidiary of Tanvex-KY, has received a Complete Response Letter (CRL) from the U.S. FDA regarding its biosimilar product TX05 (Herceptin biosimilar), due to inspection issues at a downstream fill-finish manufacturing facility.
AI Analysis
Frequently Asked Questions
Q: What is Tanvex-KY's TX05 product?
A: A Herceptin biosimilar intended for breast and gastric cancer treatment.
Q: Why did the FDA delay approval?
A: Due to inspection issues at the downstream fill-finish facility, not the drug substance.
Q: What are the next steps?
A: Submit corrective actions by end-July 2026 and prepare for re-review.
Q: How does this affect investors?
A: Approval delay may postpone revenue, increasing short-term stock volatility.
Q: What is the U.S. market size?
A: Approximately USD 1 billion in sales over the past year as of March 2026.